Roche’s Alecensa Goes Up Against Zykadia with First-Line NSCLC US FDA Approval

 
• By Alexandra Shimmings
  
Swimmers swimming in lanes
Alecensa has a competitive edge in ALK-positive NSCLC • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip